Pfizer(US:PFE) news flash·2025-04-14 10:55Group 1 - Pfizer's stock fell over 3% in pre-market trading after the company abandoned the development of its weight loss drug Danuglipron due to potential drug-induced liver damage observed in participants [1] - Competitors Eli Lilly and Novo Nordisk saw their stocks rise, with Eli Lilly increasing by 2.5% and Novo Nordisk by nearly 4% in pre-market trading [1] Group 2 - Pfizer's pre-market trading volume was reported at 2.8558 million shares, with a closing price of $21.910, reflecting a 1.48% increase from the previous close [2] - The stock's pre-market price was noted at $22.429, showing a 2.37% increase, while the lowest price recorded was $21.285 [2] - Pfizer's total market capitalization stands at approximately $124.171 billion, with a price-to-earnings ratio (TTM) of 15.54 [2]